Mr. James L.L. Tullis founded (in 1986) and remains Chairman of Tullis Health Investors (“THI”) which invests in the healthcare industry and has created and managed eight different health care-focused venture funds. THI’s funds have been lead investors in successful biotech, pharmaceutical, medical device, medical service and healthcare IT companies, including Adams Respiratory Therapeutics, Genoptix, Synageva, Biorexis, Atritech, Exagen Diagnostics, Alphatec Holdings, PSS World Medical, Impulse Monitoring, Vidacare, and others.

Prior to founding Tullis Health Investors, Mr. Tullis ‘s career was on Wall Street; where he was a Principal and managed healthcare investment research at Morgan Stanley and served as a Senior Vice President and led health care investment banking efforts at E.F. Hutton. While at Morgan Stanley, Mr. Tullis was listed 14 times on the Institutional Investor All-Star list of Wall Street’s top securities analysts; he was twice named Number 1 Drug Analyst; and he was featured on the Wall Street Week television program. Prior to that, he was a Research Analyst at Putnam Funds.

Roles and Tenure:

• Lord Abbett Mutual Funds: Chairman of the Board since 2107; Director/Trustee since 2006
• Crane Co. (NYSE: CR): Chairman of the Board since April 2020; Director since 1998
• Exagen Diagnostics (Nasdaq: XGN); Director since 2015
• Alphatec Holdings (Nasdaq: ATEC); Director since 2018